Aquestive Therapeutics Inc (AQST) Stock Analysis
Verdict: WATCH (do not buy)
Commercialization of Libervant via Eton provides revenue runway, but $53M annual cash burn and negative equity constrain fundamental upside.
Investment score: 44/100
Analysis as of
Is Aquestive Therapeutics Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assesses AQST as a WATCH due to heavy annual operating losses (-$69.7M in 2025) and negative equity (-$33.7M), balanced by $121.2M in cash liquidity and commercial out-licensing progress for Libervant.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 48/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 42/100 (weight 15%)
Aquestive Therapeutics Inc opportunities and risks
What speaks for AQST
- Eton Pharmaceuticals Licensing Deal for LIBERVANT
What speaks against AQST
- Heavy Cash Burn and Deficit Net Equity (-$33.7M)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AQST | n/a | 10.7x | n/a | 67.0% | -144.6% | -7.9% |
| COLL | 14.7x | 0.9x | 3.1x | 60.0% | 5.9% | 44.8% |
| LXRX | n/a | 17.2x | n/a | 98.9% | -147.4% | -11.2% |
| PHAT | n/a | 2.5x | n/a | 82.9% | -41.3% | -6.1% |
| Peer median | n/a | 2.5x | n/a | 82.9% | -41.3% | -6.1% |
Frequently asked questions about Aquestive Therapeutics Inc (AQST)
Is AQST stock a good investment?
The TradeMates model rates Aquestive Therapeutics Inc as WATCH (do not buy) with an investment score of 44/100. The TradeMates model assesses AQST as a WATCH due to heavy annual operating losses (-$69.7M in 2025) and negative equity (-$33.7M), balanced by $121.2M in cash liquidity and commercial out-licensing progress for Libervant. This is algorithmic model output, not personal investment advice.
Is AQST stock a buy?
The TradeMates model verdict for AQST is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.